Even as officials at Canada's National Research Universal (NRU) reactor, which supplies 50 percent of the world's medical isotope, molybdenum-99, said the plant will be shut down until later this year, Lantheus Medical Imaging says it has received FDA's nod to use low-enriched uranium from the Open Pool Australian Light-water (OPAL) reactor, as a substitute for NRU's product.
Before scrambling to diversify this spring, Lantheus' main supplier was the NRU.
FDA's approval of OPAL's low-enriched uranium (LEU) helps avert what would have been a severe shortage of parent compound MO-99 and of technetium-99m (Tc-99m), the medical isotope made from it.
For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.
Tc-99m is used in about 80 percent of nuclear medicine procedures worldwide, including positron emission tomography, single photon emission CTs and cardiac stress tests.
Netherlands Reactor to Shut Down for Repairs
FDA's approval of the LEU-derived isotopes comes at a critical time, not only for Lantheus but for other producers, as well. This is because in addition to the NRU shutdown, the other world-class reactor in The Netherlands--which produces from 30 to 40 percent of global MO-99 supply--is scheduled to be shut down for repairs from July 18 to August 19. Without LEU from Australia, U.S. hospitals would have been hard-pressed to conduct imaging exams.
Two-year old OPAL is the newest of six reactors worldwide that produce Mo-99. So far, FDA has approved four of them in Belgium, Canada, France and The Netherlands, observers say. Most of the U.S. supply still comes from Canada's 51-year old NRU reactor. The plant was shuttered in May when a heavy water leak was discovered.
As demand for medical isotopes increases, most of the reactors used to produce Tc-99m are almost a half century old and ailing. "Currently, 95 percent of the world's needs are supplied by only five reactors, all of them over 40 years old," Luis Echavarri, director general of France's Nuclear Energy Agency (NEA), said in a statement following an international meeting held in Paris last month to discuss the supply problem.
No Terror Threat With LEU
Lantheus says that "the use of LEU-based plants represents a new alternative for Mo-99 suppliers that is in line with current nonproliferation efforts in the U.S. and abroad," as LEU cannot be used as an instrument for terrorism.
"While there are currently no reactors that use LEU targets in the U.S., the nuclear medicine community recognizes the need for a domestic source of Mo-99 to accommodate U.S. and global demand as well as to minimize and eventually eliminate HEU exportation," Lantheus says.